Manmeet Ahluwalia MD, FACP, MBADeputy Director, Chief of Medical Oncology, and Chief Scientific Officer, Miami Cancer Institute, Miami, Florida
Dr. Manmeet Ahluwalia is the Deputy Director, Chief of Medical Oncology, Chief Scientific Officer, Miami Cancer Institute, Miami, Florida, Previously, he was the Dean and Diane Miller Family Endowed Chair in Neuro-Oncology in the Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center (BBTC), Cleveland Clinic, where he subspecialized in treatment of patients with brain tumors and brain metastases. He was also a Professor in the Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. He is the Associate Director, and Head of Operations in the BBTC of the Neurological Institute of Cleveland Clinic.
After receiving his medical degree from Maulana Azad Medical College, University of Delhi, India, Dr. Ahluwalia underwent residency training in internal medicine at Fairview Hospital, Cleveland Clinic Health System, and completed fellowship training in hematology/oncology at the Roswell Park Cancer Institute, University of Buffalo in Buffalo, New York.
Dr. Ahluwalia's research focuses on the development of new therapies for patients with brain tumors and brain metastases. He is currently leading several clinical trials involving new targeted therapies as well immunotherapeutic approaches. His research has been presented nationally and internationally and has resulted in over 175 editorials, peer-reviewed manuscripts, and book chapters.
Dr. Ahluwalia is a fellow in the American College of Physicians and has served in multiple leadership positions in the professional societies. He serves in editorial capacities for several journals and has been recipient of several prestigious awards such the National Cancer Institute/ CTEP Career Development Award for Clinical Trial in American Brain Tumor Consortium (ABTC), American Society of Clinical Oncology (ASCO) Leadership Development Program award, Crain’s 40 Under 40 award and has been nominated to the Leading in Healthcare, Cleveland Clinic.
Dean and Diane Miller Family Endowed Chair in Neuro-Oncology, Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute and Taussig Cancer Institute, Cleveland Clinic; Professor, Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio
MBBS: Maulana Azad Medical College, University of Delhi, India
Fellowship (hematology/oncology): Roswell Park Cancer Institute, University of Buffalo, Buffalo, New York
Novel treatments for brain tumors and brain metastases
Recent Contributions to PracticeUpdate:
- SurVaxM for Newly Diagnosed Glioblastoma
- Ruxolitinib With Temozolomide and Radiation for High-Grade Glioma
- Genomic Analysis of Patients With NSCLC-Associated Brain Metastases
- Tumor Genomic and Gut Microbiota Association With Clinical Outcomes in Newly Diagnosed Glioblastoma Treated With Atezolizumab, Temozolomide, and Radiation
- Veliparib Plus Temozolomide for MGMT Promoter Hypermethylated Glioblastoma
- Proton Craniospinal Irradiation With Photon Involved-Field Radiotherapy for Solid Tumor Leptomeningeal Metastasis
- Intramuscular INO-5401 + INO-9012 With Cemiplimab in Newly Diagnosed Glioblastoma
- Chemoradiotherapy With Temozolomide Plus Nivolumab or Placebo for Newly Diagnosed Glioblastoma With Methylated MGMT Promoter
- ASTRO Guidelines on Radiation Therapy for Brain Metastases
- The End-of-the-Road for Immunotherapies in GBM or New Opportunities for More Nuanced/aggressive Approaches? CheckMate 498